.png)
Oncology Updates - Key Oncology News
- Oncofocus Team
- 3 days ago
- 2 min read
March 2nd Week, 2025
Mergers & Acquisitions
🤝 Checkpoint Therapeutics Inc is set to be acquired by SUN PHARMA, an Indian pharma giant. This deal will strengthen Sun Pharma’s onco-dermatology portfolio, as it includes Unloxcyt (cosibelimab-ipdl), an FDA-approved anti-PD-L1 treatment indicated for advanced cutaneous squamous cell carcinoma (cSCC) (Ref 1)
❓ How will this acquisition position Sun Pharma in the immuno-oncology space? What is the indication expansion strategy for cosibelimab?
Regulatory Events
🎯 Merck & Co./MSD & Kelun-Biotech's Jiataile (sacituzumab tirumotecan; sac-TMT; TROP2 ADC) received approval in China for the treatment of EGFR mutant locally advanced or metastatic NSCLC patients who have progressed on TKI and platinum-based chemo. Sac-TMT is also approved for the treatment of TNBC in China (Ref 2)
❓ How does sac-TMT differ in efficacy from the other immuno-oncology agents approved for these indications? When is it expected to launch in the US and Europe?
🎯 Jiangsu Hansoh Pharmaceutical Group Co., Ltd.’s aumolertinib mesilate (third-generation EGFR TK inhibitor) has been approved in China as a maintenance therapy for unresectable stage III NSCLC with EGFR exon 19 deletions or exon 21 L858R mutations, who have not progressed following definitive plat chemoradiation therapy (Ref 3)
❓ Are there any other maintenance therapies approved for unresectable, Stage III, EGFR+ve NSCLC patients in China?
🎯 Health Canada approved Johnson & Johnson & Yuhan's Lazcluze (lazertinib; third-generation EGFR TK inhibitor) + J&J’s Rybrevant (amivantamab; EGFR x MET BsAb) for the treatment of EGFR mutant, metastatic NSCLC patients (Ref 4)
❓ Are there other targeted therapies approved for EGFR-positive NSCLC patients in Canada? Additionally, what potential challenges might the combination therapy face during clinical adoption?
To know answers to these questions and for additional insights, write to us at support@oncofocus.com
🌐 References:
Comments